Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)

被引：0
|
作者：
Valencak, J
Lathan, B
Kornek, G
Raderer, M
Klein, G
Hejna, M
Brodovic, T
Weinländer, G
Depisch, D
Scheithauer, W
机构：
[1] Univ Vienna, Dept Int Med 1, Vienna, Austria
[2] Lathan Inst, Dortmund, Germany
[3] Wr Neustadt Gen Hosp, Neustadt, Germany
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [1] Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)
    Scheithauer, W
    Lathan, B
    Kornek, G
    Raderer, M
    Valencak, J
    Klein, G
    Hejna, M
    Brodovic, T
    Weinlander, G
    Depisch, D
    ANNALS OF ONCOLOGY, 1998, 9 : 172 - 172
  • [2] Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials
    Goldberg, RM
    Erlichman, C
    ONCOLOGY-NEW YORK, 1998, 12 (08): : 59 - 63
  • [3] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [4] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis
    Guo, Yuanbiao
    Shi, Min
    Shen, Xiaoheng
    Yang, Chen
    Yang, Liu
    Zhang, Jun
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 110 - 118
  • [6] A phase II study of weekly oxaliplatin and high dose 5-FU with LCV as second line therapy in patients with advanced colorectal cancer
    Janinis, J
    Fountzilas, G
    Papakostas, P
    Efstathiou, E
    Valagouti, D
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 44
  • [7] Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Twelves, C
    ONCOLOGY-NEW YORK, 2002, 16 (12): : 23 - 26
  • [8] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
    Masi, G
    Allegrini, G
    Marcucci, L
    Cupini, S
    Brunetti, I
    Fontana, E
    Ricci, S
    Cerri, E
    Barbara, C
    Falcone, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [9] Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer
    Lee, S. C.
    Lee, K.
    Bae, S. B.
    Kim, Han Jo
    Oh, S. Y.
    Song, S. Y.
    Hong, D. S.
    Kim, Hyun Jung
    Yoon, J.
    Lim, D. H.
    Lee, S. I.
    Won, J. H.
    Lee, N.
    Kim, K.
    Lee, H. W.
    Lee, H. R.
    Nam, E. M.
    Jang, J. S.
    Hwang, I. G.
    Kang, J. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S456 - S456
  • [10] A phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU versus the Leucovorin Calcium followed by 5-FU both in combination with Irinotecan or Oxaliplatin in patients with metastatic colorectal cancer
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezaei
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01): : 14 - 21
12345